You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AKT pan inhibitor

Showing 1 - 25 of 8,258
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bile Acids in Acute Insulin Resistance

Recruiting
  • PI3K Gene Mutation
  • +4 more
  • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
  • New York, New York
    Columbia University Medical Center
Oct 6, 2022

Advanced Malignant Solid Tumor, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7 Trial in New Brunswick

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jan 25, 2023

Advanced Solid Tumors Trial in Cincinnati, Houston, Salt Lake City (YL-17231)

Not yet recruiting
  • Advanced Solid Tumors
  • Cincinnati, Ohio
  • +2 more
Oct 22, 2023

PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only

Not yet recruiting
  • PARP Inhibitor for Esophageal Squamous Cell Carcinoma
  • Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
  • (no location specified)
Sep 24, 2023

CNS Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Houston (Akt/ERK Inhibitor ONC201,

Terminated
Has Results
  • Central Nervous System Lymphoma
  • +6 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 30, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 10, 2022

Advanced Solid Tumor Trial in Guangzhou (YL-17231)

Recruiting
  • Advanced Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 5, 2023

Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

Recruiting
  • Premenopausal Breast Cancer
  • +2 more
  • Taipei City, Taiwan
    Department of Oncology, National Taiwan University Hospital
Feb 7, 2023

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +4 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +6 more
Jan 13, 2022

Esophageal Cancer Trial in Hat yai (BKM120)

Terminated
  • Esophageal Cancer
  • Hat yai, Songkhla, Thailand
    Songklanagarind Hospital, Prince of Songkla University
Oct 3, 2021

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis Trial in United States (procedure, drug,

Not yet recruiting
  • Colorectal Adenomatous Polyp
  • +3 more
  • Biopsy
  • +5 more
  • Ann Arbor, Michigan
  • +4 more
Jan 3, 2023

Breast Cancer Trial in Boston (Ipatasertib, Fulvestrant, Aromatase Inhibitor)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Oct 25, 2021

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

Triple Negative Breast Cancer Trial in Madison (Akt/ERK Inhibitor ONC201, Methionine-Restricted Diet)

Terminated
Has Results
  • Triple Negative Breast Cancer
  • Akt/ERK Inhibitor ONC201
  • Methionine-Restricted Diet
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Feb 11, 2022

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023

Low-grade Glioma Trial (Tovorafenib)

Available
  • Low-grade Glioma
  • (no location specified)
Feb 23, 2023

Uveitis Trial in United States (Izokibep, Prednisone/Prednisolone)

Active, not recruiting
  • Uveitis
  • Los Angeles, California
  • +3 more
Jul 18, 2022

Estrogen Receptor Positive Breast Cancer Trial in United Kingdom (AZD5363, Placebo, Fulvestrant)

Active, not recruiting
  • Estrogen Receptor Positive Breast Cancer
  • Manchester, Greater Manchester, United Kingdom
  • +20 more
Aug 5, 2022

Seborrheic Keratosis Trial in Santa Tecla (SM-020)

Recruiting
  • Seborrheic Keratosis
  • Santa Tecla, La Libertad, El Salvador
    Zepeda Dermatologia
Aug 20, 2022

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic

Not yet recruiting
  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • (no location specified)
Sep 13, 2022

Advanced Solid Tumors Harboring MAPK Pathway Alterations Trial in Shandong (QLH11906)

Recruiting
  • Advanced Solid Tumors Harboring MAPK Pathway Alterations
  • Shandong, China
    Shandong Cancer Hospital
Aug 3, 2022

Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis Trial (Biopsy, Biospecimen Collection,

Not yet recruiting
  • Recurrent Langerhans Cell Histiocytosis
  • Refractory Langerhans Cell Histiocytosis
  • Biopsy
  • +3 more
  • (no location specified)
Dec 22, 2022

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma Trial in Houston (AL101, Therapeutic Conventional Surgery)

Recruiting
  • Adenoid Cystic Carcinoma
  • Metastatic Adenoid Cystic Carcinoma
  • AL101
  • Therapeutic Conventional Surgery
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

Recruiting
  • Metastatic Breast Cancer
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022